Cigna Group (NYSE: CI) posted fourth‑quarter 2025 results that beat consensus estimates, with revenue of $72.5 billion—up 10% from $65.6 billion in Q4 2024—and adjusted earnings per share of $8.08, a $0.20 beat over the $7.88 consensus. Adjusted income from operations for the quarter was $2.10 billion, slightly below the $2.15 billion originally reported but still a 10% year‑over‑year increase from $1.90 billion in Q4 2024.
The growth was driven primarily by Evernorth Health Services, which generated $63.1 billion in revenue, a 12% rise from $56.0 billion in the same quarter last year. Cigna Healthcare contributed $11.2 billion, a modest 3% increase, while the Pharmacy Benefit Management (PBM) segment saw a 20% jump in sales, reflecting the momentum behind the company’s rebate‑free pharmacy model. These segment gains offset a 1% decline in legacy Medicare revenue following the sale of that business to Health Care Service Corp. (HCSC).
Margin performance remained under pressure, with the medical cost ratio (MCR) rising to 88% in Q4 2025 from 87.9% in Q4 2024, and the full‑year 2025 MCR at 84.4% versus 83.2% in 2024. The higher MCR reflects increased medical costs in the individual and family plans business, while the company’s cost‑control initiatives in Evernorth helped keep operating margins from deteriorating further. Adjusted operating income rose to $2.10 billion, a 10% increase from $1.90 billion in Q4 2024, driven by the stronger mix of high‑margin specialty pharmacy and health‑services revenue.
Full‑year 2025 adjusted revenue reached $274.9 billion, up 11% from $247.1 billion in 2024, and adjusted EPS climbed to $29.84, a 9% increase from $27.33 in the prior year. The year‑over‑year revenue growth was largely attributable to the 12% rise in Evernorth revenue and the 20% increase in PBM sales, while the modest decline in Medicare revenue was offset by gains in other segments.
Management guided 2026 adjusted revenue to approximately $280 billion, a modest 2% increase from the prior year, and adjusted income from operations to at least $7.95 billion, or $30.25 per share. CEO David Cordani emphasized that the guidance reflects a focus on margin recovery in the healthcare segment and continued investment in the rebate‑free pharmacy model. He noted that “we are well‑positioned to build on this momentum, fueled by our diversified businesses and track record of strong financial performance.”
Market reaction to the results was muted, with investors weighing the earnings beat against the slightly below‑consensus 2026 guidance. Analysts highlighted the company’s strong segment performance but expressed concern over the rising MCR and the impact of the Medicare sale on future revenue streams. The guidance signals a cautious outlook, suggesting management anticipates near‑term margin pressure while remaining confident in long‑term growth from Evernorth and the PBM platform.
Strategically, the results reinforce Cigna’s shift toward a more integrated health‑services model. The continued expansion of Evernorth and the rebate‑free pharmacy initiative position the company to capture higher‑margin opportunities, while the sale of its Medicare business reduces exposure to a segment that has been under pressure from regulatory and cost‑inflation headwinds. These moves are expected to improve the company’s risk profile and support sustainable earnings growth over the next few years.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.